Y0000721
Mirtazapine for system suitability
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Mirtazapine, 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C17H19N3
CAS Number:
Molecular Weight:
265.35
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
mirtazapine
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
CN1CCN2C(C1)c3ccccc3Cc4cccnc24
InChI
1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
InChI key
RONZAEMNMFQXRA-UHFFFAOYSA-N
유전자 정보
human ... ADRA2A(150) , ADRA2B(151) , ADRA2C(152) , HTR2A(3356) , HTR2C(3358)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Mirtazapine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
생화학적/생리학적 작용
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - STOT SE 3
표적 기관
Central nervous system
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Hun Soo Chang et al.
Journal of neural transmission (Vienna, Austria : 1996), 122(1), 59-68 (2014-12-03)
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening
Katarzyna Kamińska et al.
Pharmacological reports : PR, 66(6), 984-990 (2014-12-03)
The aim of our study was to understand the mechanism of clinical efficacy of the combination of an antidepressant and risperidone in drug-resistant depression. We studied the effect of an antidepressant (mirtazapine) and risperidone (atypical antipsychotic), given separately or jointly
Andrea de Bejczy et al.
Journal of clinical psychopharmacology, 35(1), 43-50 (2014-12-18)
The number of therapeutic drugs available for the treatment of alcohol use disorders (AUDs) is limited, and a well-tolerated, self-administrable drug is much needed. Subgroups of alcohol-dependent individuals, for example, individuals with heredity for AUD, may respond differently to pharmacological
Michael Paulzen et al.
Psychopharmacology, 232(4), 807-813 (2014-08-26)
The aim of this study was to investigate the distribution pattern of mirtazapine and its metabolite normirtazapine (N-desmethylmirtazapine) in blood and cerebrospinal fluid (CSF). Concentrations of mirtazapine were measured in blood serum and CSF of 16 patients treated with daily
Jui-Hsiu Tsai et al.
International journal of molecular sciences, 15(8), 13223-13235 (2014-07-30)
Major depressive disorder and cardiovascular disease are common serious illnesses worldwide. Selective serotonin reuptake inhibitors and norepinephrine-dopamine reuptake inhibitors may reduce the mortality of cardiovascular disease patients with comorbid depression. Interferon-γ-inducible protein 10 (IP-10), a type 1 T helper cell
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.